Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + cetuximab vs FOLFIRI + cetuximab in BRAF V600E-mutant metastatic colorectal cancer (China bridge study)
CTR20210687Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib in colorectal cancer (CRC), sponsored by Pierre Fabre Laboratories. Started Jun 2021; status: completed.
02
Drugs
encorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20210687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210687.